SuperworthHalozyme Therapeutics shares outstanding HALO
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 121.2M
- On a year earlier
- −2.4%
- fewer shares
Halozyme Therapeutics had 121.2M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 2.4% fewer than a year earlier, so each share owns a little more of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 117.7M | −9% |
| FY2024 | 129.1M | −2% |
| FY2023 | 131.1M | −6% |
| FY2022 | 139.4M | −3% |
| FY2021 | 144.3M | −1% |
| FY2020 | 145.1M | +3% |
| FY2019 | 141M | −2% |
| FY2018 | 144.2M | −1% |
| FY2017 | 145.6M | +14% |
| FY2016 | 128.2M | +3% |
| FY2014 | 124.3M | +9% |
| FY2013 | 113.6M | +1% |
| FY2012 | 112.3M | +9% |
| FY2011 | 103.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 121.2M | −2% | |
| Q1 FY26 | 122.9M | −3% | |
| Q4 FY25 | 117.7M | −9% | |
| Q3 FY25 | 122.3M | −6% | |
| Q2 FY25 | 124.2M | −4% | |
| Q1 FY25 | 126.6M | −2% | |
| Q4 FY24 | 129.1M | −2% | |
| Q3 FY24 | 130.1M | −3% | |
| Q2 FY24 | 129.2M | −3% | |
| Q1 FY24 | 128.9M | −7% | |
| Q4 FY23 | 131.1M | −6% | |
| Q3 FY23 | 134.1M | −4% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Halozyme Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.